Lab
Alphadera Labs,llc
Alphadera Labs,llc was paid $1.20M by Medicaid between Jun 2020 and Feb 2024, across 31 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 76% of everything it billed.
33Billing provider infoALPHADERA LABS,LLC
HOUSTON, TX 77032
HOUSTON, TX 77032
33aNPI1467946848assigned 06/19/2018
33bProvider typeClinical Medical Laboratory
28Total paid$1.20M
24GClaims32,044
24DCodes billed31
24AFirst – last monthJun 2020 – Feb 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#64 of 436
Median peer was paid$17K
This provider vs. median70×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,500 | $168K | |
| 2021 | 17,733 | $732K | |
| 2022 | 8,184 | $270K | |
| 2023 | 3,599 | $31K | |
| 2024incomplete | 28 | $879.89 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 76% | 14,256 | 11,645 | $911K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 19% | 11,165 | 8,773 | $222K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.7% | 2,169 | 1,919 | $32K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.4% | 350 | 329 | $16K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 282 | 260 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 142 | 118 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 316 | 301 | $4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 1,382 | 1,359 | $2K |
| 87653 | <1% | 259 | 249 | $669.22 | |
| 87640 | <1% | 150 | 149 | $378.83 | |
| 87481 | <1% | 150 | 149 | $378.83 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 128 | 120 | $316.98 |
19 more codes
| 80061 | Lipid panel | <1% | 221 | $275.65 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 172 | $135.85 |
| 87631 | <1% | 14 | $113.82 | |
| 82607 | <1% | 125 | $100.10 | |
| 82746 | <1% | 121 | $97.56 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 56 | $28.22 |
| 80053 | Comprehensive metabolic panel | <1% | 119 | $17.74 |
| 81001 | <1% | 51 | $10.64 | |
| 84439 | <1% | 17 | $7.58 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 78 | $6.53 |
| 83735 | <1% | 16 | $5.63 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 162 | $0.00 |
| 84436 | 0% | 12 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 14 | $0.00 |
| 84480 | 0% | 12 | $0.00 | |
| 80050 | General health panel | 0% | 12 | $0.00 |
| 87150 | 0% | 46 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 34 | $0.00 |
| 84481 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialADU, HEINDEL (PRESIDENT)